# Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

> **NCT01064622** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 118 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma
- Recurrent Pancreatic Carcinoma
- Stage IV Pancreatic Cancer AJCC v6 and v7

## Interventions

- **DRUG:** Gemcitabine Hydrochloride
- **OTHER:** Hydrocortisone/Placebo
- **DRUG:** Vismodegib

## Key facts

- **NCT ID:** NCT01064622
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-03
- **Primary completion:** 2012-12-09
- **Final completion:** 2013-01-31
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01064622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01064622, "Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01064622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*